Galapagos NV (WBO:GLPG) Land And Improvements : €0.0 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Galapagos NV Land And Improvements?

Galapagos NV's land and improvements for the quarter that ended in Sep. 2024 was €0.0 Mil.

Galapagos NV's annual land and improvements increased from Dec. 2021 (€26.1 Mil) to Dec. 2022 (€88.7 Mil) and increased from Dec. 2022 (€88.7 Mil) to Dec. 2023 (€90.7 Mil).

Galapagos NV Land And Improvements Historical Data

The historical data trend for Galapagos NV's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Land And Improvements Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

5.28

16.74

26.13

88.72

90.71

Galapagos NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Land And Improvements	Get a 7-Day Free Trial															-	90.71	-	-	-

Galapagos NV Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (WBO:GLPG) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.